The generic name for Anoro Ellipta is umeclidinium/vilanterol [1].
What conditions does umeclidinium/vilanterol treat?
Umeclidinium/vilanterol is a long-acting bronchodilator used to manage airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema [2]. It is not a rescue inhaler and should not be used to treat sudden breathing problems [2].
How does umeclidinium/vilanterol work?
This medication combines two bronchodilators: umeclidinium, an anticholinergic, and vilanterol, a long-acting beta2-adrenergic agonist (LABA) [3]. Umeclidinium works by blocking the action of acetylcholine on airway smooth muscle, leading to bronchodilation. Vilanterol stimulates beta2-adrenergic receptors in the lungs, causing relaxation of airway smooth muscle and also resulting in bronchodilation [3].
What are the alternatives to Anoro Ellipta?
Several other inhalers are used for COPD management. These include other combinations of long-acting bronchodilators, such as those containing tiotropium, olodaterol, indacaterol, or formoterol [4]. Some treatments also involve inhaled corticosteroids, often in combination with long-acting bronchodilators, such as fluticasone furoate/umeclidinium/vilanterol or budesonide/formoterol [4]. The choice of treatment depends on the severity of COPD, individual patient response, and physician recommendation [4].
When does patent protection for Anoro Ellipta expire?
Information on patent expiry dates for Anoro Ellipta can be found on specialized drug patent tracking websites [5]. These resources track patents to indicate when generic versions of a drug may become available.